Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
Titel:
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
Auteur:
Zhou, Caicun Wu, Yi-Long Chen, Gongyan Feng, Jifeng Liu, Xiao-Qing Wang, Changli Zhang, Shucai Wang, Jie Zhou, Songwen Ren, Shengxiang Lu, Shun Zhang, Li Hu, Chengping Hu, Chunhong Luo, Yi Chen, Lei Ye, Ming Huang, Jianan Zhi, Xiuyi Zhang, Yiping Xiu, Qingyu Ma, Jun Zhang, Li You, Changxuan